Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Overcoming limits for pre-clinical small volume liquid delivery into skin and inflammation quantification

Project description

Needle-free drug delivery for chronic skin conditions

Chronic inflammation in the skin, commonly due to allergy, infection or autoimmune disease, necessitates prolonged treatment, posing a significant challenge in the lives of patients. The ERC-funded Lab-In-Skin project aims to revolutionise skin disease treatment through BuBble Gun, a needle-free technology for injecting biologics directly into skin lesions. This approach represents a shift from systemic dosing to targeted local delivery, potentially enhancing treatment efficacy. To validate this method, the project will employ Skin-On-Chip technology to test the BuBble Gun’s effectiveness in the delivery of various drugs for conditions like eczema and psoriasis.

Objective

Chronic inflammatory skin diseases have a huge burden on patients, their families, and the economy. New patient-friendly delivery methods are urgently needed targeting immune cells in the dermis. Injecting small volumes of biologics directly in skin lesions using needle-free technology would revolutionize treatments and shift the systemic dosing paradigm to individualized local dosing.
However, to realize this vision, there is a long path to test its effectiveness in pre-clinical (in vitro, ex vivo) and clinical studies. First, testing new drugs is costly and often involves tests with animals with poor translational value because of differences in skin anatomy with humans.
Therefore, with this project, we will establish the proof of concept that BuBble Gun, a minimal invasive injection method can effectively be used for innovative drug testing via Skin-On-Chip technology.
We will study in vitro skin inflammation response with plasma activated water and active pharmaceutic ingredients used in treating skin diseases such as eczema (atopic dermatitis) and psoriasis. Lastly, in collaboration with several stakeholders, we will prepare a business plan to clear the way for further developments and establish the best path to revolutionize drug delivery into skin and cosmetics.

Fields of science (EuroSciVoc)

Programme(s)

Topic(s)

Funding Scheme

HORIZON-ERC-POC - HORIZON ERC Proof of Concept Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2024-POC

See all projects funded under this call

Host institution

UNIVERSITEIT TWENTE
Net EU contribution
€ 150 000,00
Address
DRIENERLOLAAN 5
7522 NB Enschede
Netherlands
Region
Oost-Nederland Overijssel Twente
Activity type
Higher or Secondary Education Establishments
Links
Total cost
No data

Beneficiaries (1)